A 12-week, randomized, double-blind, placebo- controlled study of PRN BID and fixed dosing regimens of alosetron in female subjects with severe diarrhea-predominant irritable bowel syndrome who have failed conventional therapy
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Alosetron (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Oct 2005 New trial record.